A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT03000257. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors
Study identification
- NCT ID
- NCT03000257
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Interventions
- ABBV-181 Drug
- Rovalpituzumab Tesirine Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2016
- Primary completion
- Mar 28, 2022
- Completion
- Mar 28, 2022
- Last update posted
- Apr 13, 2022
2016 – 2022
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores Cancer Center at UC San Diego /ID# 157374 | La Jolla | California | 92093 | — |
| The University of Chicago Medical Center /ID# 157375 | Chicago | Illinois | 60637-1443 | — |
| Carolina BioOncology Institute /ID# 157376 | Huntersville | North Carolina | 28078 | — |
| South Texas Accelerated Research Therapeutics /ID# 157378 | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists - Fairfax /ID# 157377 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03000257, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2022 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03000257 live on ClinicalTrials.gov.